PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer. J Evid Based Med Res [Internet]. 2026 Sep. 1 [cited 2026 Oct. 4];2(03):58-69. Available from: https://jebmr.com/index.php/home/article/view/43